Octreotide
FDA ApprovedAlso known as: Sandostatin, Sandostatin LAR
Somatostatin AnalogLast reviewed: April 28, 2026
A synthetic octapeptide analog of somatostatin with a much longer half-life than the natural hormone. FDA-approved for acromegaly, carcinoid tumors, and VIPomas. One of the foundational peptide drugs in endocrinology.
Mechanism of Action
Binds to somatostatin receptors (primarily SSTR2 and SSTR5), inhibiting growth hormone, glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits GI motility and secretion.
Common Uses
- Acromegaly
- Carcinoid syndrome
- VIPomas
- GI bleeding (variceal)
- Dumping syndrome
Known Risks
- Gallstones (common with long-term use)
- GI side effects (diarrhea, nausea)
- Hyperglycemia or hypoglycemia
- Injection site pain
- Bradycardia
Regulatory Status
FDA-approved as Sandostatin (1988, subcutaneous) and Sandostatin LAR (1998, monthly depot). Generic octreotide available. Widely used in endocrinology and oncology.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection / IM depot
Typical Dose
50–200 mcg SC 2–3x daily; or 10–30 mg LAR monthly
Frequency
SC: 2–3x daily; LAR: once monthly
Cycle Length
Ongoing for chronic conditions
LAR (long-acting release) depot is preferred for chronic use. SC injections used for acute management and dose titration.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.